1 서수현, "Whole Exome Sequencing Identifies Novel Genetic Alterations in Patients with Pheochromocytoma/Paraganglioma" 대한내분비학회 35 (35): 909-917, 2020
2 DeLellis RA, "WHO classification of tumours: pathology and genetics of tumours of endocrine organs" IARC 2004
3 Lloyd RV, "WHO classification of tumours: pathology and genetics of tumours of endocrine organs" IARC Press 2017
4 Milardovic R, "Value of 123IMIBG scintigraphy in paraganglioma" 91 : 94-100, 2010
5 Koh JM, "Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma" 12 : e0187398-, 2017
6 Wiseman GA, "Usefulness of 123IMIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma : results from a prospective multicenter trial" 50 : 1448-1454, 2009
7 Pillai S, "Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era" 100 : 190-208, 2016
8 Lam AK, "Update on adrenal tumours in 2017 World Health Organization(WHO)of endocrine tumours" 28 : 213-227, 2017
9 Adjalle R, "Treatment of malignant pheochromocytoma" 41 : 687-696, 2009
10 Stenman A, "The value of histological algorithms to predict the malignancy potential of pheochromocytomas and abdominal paragangliomas: a metaanalysis and systematic review of the literature" 11 : 225-, 2019
11 Wang Y, "The systems of metastatic potential prediction in pheochromocytoma and paraganglioma" 10 : 769-780, 2020
12 Grossrubatscher E, "The role of chromogranin A in the management of patients with phaeochromocytoma" 65 : 287-293, 2006
13 Brito JP, "Testing for germline mutations in sporadic pheochromocytoma/paraganglioma: a systematic review" 82 : 338-345, 2015
14 Ben Aim L, "Targeted next-generation sequencing detects rare genetic events in pheochromocytoma and paraganglioma" 56 : 513-520, 2019
15 Cho YY, "Symptom-dependent cut-offs of urine metanephrines improve diagnostic accuracy for detecting pheochromocytomas in two separate cohorts, compared to symptom-independent cut-offs" 54 : 206-216, 2016
16 Janssen I, "Superiority of [68Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma" 21 : 3888-3895, 2015
17 Amar L, "Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas" 92 : 3822-3828, 2007
18 Agarwal A, "Size of the tumor and pheochromocytoma of the adrenal gland scaled score (PASS): can they predict malignancy?" 34 : 3022-3028, 2010
19 Pillai S, "Silent genetic alterations identified by targeted next-generation sequencing in pheochromocytoma/paraganglioma : a clinicopathological correlations" 102 : 41-46, 2017
20 Lumachi F, "Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localizing pheochromocytomas : a prospective study" 27 : 583-587, 2006
21 Papathomas TG, "SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas : a multicenter interobserver variation analysis using virtual microscopy. A multinational study of the European Network for the Study of Adrenal Tumors(ENS@T)" 28 : 807-821, 2015
22 Pasini B, "SDH mutations in tumorigenesis and inherited endocrine tumours : lesson from the phaeochromocytoma-paraganglioma syndromes" 266 : 19-42, 2009
23 Kimura N, "Risk stratification on pheochromocytoma and paraganglioma from laboratory and clinical medicine" 7 : 242-, 2018
24 Kulkarni MM, "Risk stratification in paragangliomas with PASS(Pheochromocytoma of the Adrenal Gland Scaled Score)and immunohistochemical markers" 10 : EC01-4-, 2016
25 Lee H, "Risk of metastatic pheochromocytoma and paraganglioma in SDHx mutation carriers : a systematic review and updated meta-analysis" 57 : 217-225, 2020
26 van Hulsteijn LT, "Quality of life is decreased in patients with paragangliomas" 168 : 689-697, 2013
27 Archier A, "Prospective comparison of(68)Ga-DOTATATE and(18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases" 43 : 1248-1257, 2016
28 Wachtel H, "Predicting metastatic potential in pheochromocytoma and paraganglioma : a comparison of PASS and GAPP scoring systems" 105 : e4661-70, 2020
29 Buffet A, "Positive impact of genetic test on the management and outcome of patients with paraganglioma and/or pheochromocytoma" 104 : 1109-1118, 2019
30 Rao D, "Plasma methoxytyramine : clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma" 177 : 103-113, 2017
31 Eisenhofer G, "Plasma methoxytyramine : a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status" 48 : 1739-1749, 2012
32 Hickman PE, "Plasma free metanephrines are superior to urine and plasma catecholamines and urine catecholamine metabolites for the investigation of phaeochromocytoma" 41 : 173-177, 2009
33 Algeciras-Schimnich A, "Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma" 93 : 91-95, 2008
34 Unger N, "Plasma and urinary metanephrines determined by an enzyme immunoassay, but not serum chromogranin A for the diagnosis of pheochromocytoma in patients with adrenal mass" 120 : 494-500, 2012
35 Pacak K, "Pheochromocytoma(PHEO)and paraganglioma(PGL)" 11 : 1391-, 2019
36 Beltsevich DG, "Pheochromocytoma surgery : epidemiologic peculiarities in children" 28 : 592-596, 2004
37 Thompson LD, "Pheochromocytoma of the Adrenal gland Scaled Score(PASS)to separate benign from malignant neoplasms : a clinicopathologic and immunophenotypic study of 100 cases" 26 : 551-566, 2002
38 Lenders JW, "Pheochromocytoma and paraganglioma : an endocrine society clinical practice guideline" 99 : 1915-1942, 2014
39 Neumann HPH, "Pheochromocytoma and paraganglioma" 381 : 552-565, 2019
40 Welch TJ, "Pheochromocytoma : value of computed tomography" 148 : 501-503, 1983
41 Han S, "Performance of 68Ga-DOTA-conjugated somatostatin receptor-targeting peptide PET in detection of pheochromocytoma and paraganglioma : a systematic review and metaanalysis" 60 : 369-376, 2019
42 Satapathy S, "Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis" 91 : 718-727, 2019
43 Kimura N, "Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma" 21 : 405-414, 2014
44 Favier J, "Paraganglioma and phaeochromocytoma : from genetics to personalized medicine" 11 : 101-111, 2015
45 Janssen I, "PET/CT comparing(68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic pheochromocytoma and paraganglioma" 43 : 1784-1791, 2016
46 Gieldon L, "Optimizing genetic workup in pheochromocytoma and paraganglioma by integrating diagnostic and research approaches" 11 : 809-, 2019
47 Plouin PF, "Metastatic pheochromocytoma and paraganglioma : focus on therapeutics" 44 : 390-399, 2012
48 Timmers HJ, "Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma" 15 : 1127-1133, 2008
49 Angelousi A, "Malignant pheochromocytomas/paragangliomas and ectopic hormonal secretion: a case series and review of the literature" 11 : 724-, 2019
50 Roman-Gonzalez A, "Malignant pheochromocytoma-paraganglioma : pathogenesis, TNM staging, and current clinical trials" 24 : 174-183, 2017
51 Szalat A, "Malignant pheochromocytoma : predictive factors of malignancy and clinical course in 16 patients at a single tertiary medical center" 39 : 160-166, 2011
52 Lenders JW, "Is supine rest necessary before blood sampling for plasma metanephrines?" 53 : 352-354, 2007
53 Maurea S, "Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas : comparison with CT and MRI" 34 : 173-179, 1993
54 van Gils AP, "Iodine-123-metaiodobenzylguanidine scintigraphy in patients with chemodectomas of the head and neck region" 31 : 1147-1155, 1990
55 Berends AMA, "Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands : a nationwide study and systematic review" 51 : 68-73, 2018
56 Gimenez-Roqueplo AP, "Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers : a multicenter prospective study from the PGL. EVA Investigators" 98 : E162-73, 2013
57 Brouwers FM, "High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas : implications for genetic testing" 91 : 4505-4509, 2006
58 Kim JH, "Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea" 86 : 482-486, 2014
59 Jochmanova I, "Genomic landscape of pheochromocytoma and paraganglioma" 4 : 6-9, 2018
60 Muth A, "Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma" 285 : 187-204, 2019
61 최희원, "Genetic Analysis and Clinical Characteristics of Hereditary Pheochromocytoma and Paraganglioma Syndrome in Korean Population" 대한내분비학회 35 (35): 858-872, 2020
62 Janssen I, "Functional imaging signature of patients presenting with polycythemia/paraganglioma syndromes" 58 : 1236-1242, 2017
63 Fonte JS, "False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease" 19 : 83-93, 2012
64 Plouin PF, "European Society of Endocrinology clinical practice guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma" 174 : G1-10, 2016
65 Taieb D, "European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma" 46 : 2112-2137, 2019
66 김정희, "Epidemiology and Prognosis of Pheochromocytoma/Paraganglioma in Korea: A Nationwide Study Based on the National Health Insurance Service" 대한내분비학회 35 (35): 157-164, 2020
67 Pryma DA, "Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma" 60 : 623-630, 2019
68 Kim KY, "Disentangling of malignancy from benign pheochromocytomas/paragangliomas" 11 : e0168413-, 2016
69 Unger N, "Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass" 154 : 409-417, 2006
70 Kim HJ, "Diagnostic accuracy of plasma free metanephrines in a seated position compared with 24-hour urinary metanephrines in the investigation of pheochromocytoma" 62 : 243-250, 2015
71 Grouzmann E, "Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma" 162 : 951-960, 2010
72 김정희, "Diagnosis and Treatment of Growth Hormone Deficiency: A Position Statement from Korean Endocrine Society and Korean Society of Pediatric Endocrinology" 대한내분비학회 35 (35): 272-287, 2020
73 Jimenez C, "Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma" 15 : 356-371, 2013
74 NGS in PPGL(NGSnPPGL)Study Group, "Consensus statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas" 13 : 233-247, 2017
75 Rufini V, "Comparison of metaiodobenzylguanidine scintigraphy with positron emission tomography in the diagnostic work-up of pheochromocytoma and paraganglioma : a systematic review" 57 : 122-133, 2013
76 Ilias I, "Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma" 49 : 1613-1619, 2008
77 Ayala-Ramirez M, "Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas : primary tumor size and primary tumor location as prognostic indicators" 96 : 717-725, 2011
78 Goldstein RE, "Clinical experience over 48 years with pheochromocytoma" 229 : 755-764, 1999
79 Choi YM, "Clinical course and prognostic factors in patients with malignant pheochromocytoma and paraganglioma : a single institution experience" 112 : 815-821, 2015
80 Barontini M, "Characteristics of pheochromocytoma in a 4-to 20-year-old population" 1073 : 30-37, 2006
81 Jung Hee Kim, "Characteristics of germline mutations in Korean patients with pheochromocytoma/paraganglioma" BMJ 59 (59): 56-64, 2022
82 Kvasnicka J, "Catecholamines induce left ventricular subclinical systolic dysfunction: a speckle-tracking echocardiography study" 11 : 318-, 2019
83 Eisenhofer G, "Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma" 18 : 97-111, 2010
84 Pierre C, "COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas" 474 : 721-734, 2019
85 Ballal S, "Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT : first clinical experience on the efficacy and safety" 47 : 934-946, 2020
86 Ayala-Ramirez M, "Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma" 98 : 1492-1497, 2013
87 Timmers HJ, "Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene" 93 : 4826-4832, 2008
88 Lenders JW, "Biochemical diagnosis of pheochromocytoma: which test is best?" 287 : 1427-1434, 2002
89 Eisenhofer G, "Biochemical and clinical manifestations of dopamine-producing paragangliomas : utility of plasma methoxytyramine" 90 : 2068-2075, 2005
90 Bisogni V, "Analysis of short-term blood pressure variability in pheochromocytoma/paraganglioma patients" 11 : 658-, 2019
91 Buffet A, "An overview of 20 years of genetic studies in pheochromocytoma and paraganglioma" 34 : 101416-, 2020
92 van Nederveen FH, "An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations : a retrospective and prospective analysis" 10 : 764-771, 2009
93 Edge SB, "American Joint Committee on Cancer. AJCC cancer staging manual" Springer 2017
94 Chen Y, "Accuracy of plasma free metanephrines in the diagnosis of pheochromocytoma and paraganglioma : a systematic review and meta-analysis" 23 : 1169-1177, 2017
95 MacFarlane J, "A review of the tumour spectrum of germline succinate dehydrogenase gene mutations: beyond phaeochromocytoma and paraganglioma" 93 : 528-538, 2020
96 Kroiss A, "A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma" 40 : 1800-1808, 2013
97 Cho YY, "A clinical prediction model to estimate the metastatic potential of pheochromocytoma/paraganglioma : ASES score" 164 : 511-517, 2018
98 Janssen I, "68Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT/MRI" 57 : 186-191, 2016
99 Fiebrich HB, "6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess" 94 : 3922-3930, 2009
100 Taieb D, "18F-FDOPA PET/CT imaging of MAX-related pheochromocytoma" 103 : 1574-1582, 2018
101 Bhatia KS, "123I-metaiodobenzylguanidine (MIBG)scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation" 69 : 181-188, 2008
102 Vyakaranam AR, "11C-hydroxy-ephedrine-PET/CT in the diagnosis of pheochromocytoma and paraganglioma" 11 : 847-, 2019
103 Kroiss A, "(68)Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to(123)I-MIBG SPECT/CT" 42 : 33-41, 2015
104 Chang CA, "(68)Ga-DOTATATE and(18)F-FDG PET/CT in paraganglioma and pheochromocytoma : utility, patterns and heterogeneity" 16 : 22-, 2016
105 van Hulsteijn LT, "(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis" 80 : 487-501, 2014